Results 181 to 190 of about 416,152 (310)

Interferon Alfa in the treatment of B-cell chronic lymphocytic leukemia [PDF]

, 1994
Adolf, D., Bergmann, L., Dietzfelbinger, H., Emmerich, B., Knauf, W. U., Langenmayer, Irmgard, Maubach, P. A., Mitrou, P. S., Nerl, C., Thiel, E., Ziegle-Heitbrock, H. W. L.   +10 more
core   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, EarlyView.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source

Astrocytes in neuroinflammation and brain cancer. [PDF]

Mol Biomed
Sun W, Chen P, Xu XY, Zhang JQ, Jin WL.
europepmc   +1 more source

Endogenous “Time Bomb” – Mislocalized Phospholipase A2 as a Critical Mediator of Ultra‐Rapid Mortality in Sepsis and Acute Lung Injury

Advanced Science, EarlyView.
Phospholipase A2 (PLA2), a dormant enzyme, becomes lethal when activated—collapsing lungs in minutes. Our dual therapy (DOPS + varespladib) boosts survival from 0% to >90% in sepsis/ALI. A breakthrough for acute lung injury treatment. ABSTRACT This study reveals that phospholipase A2 (PLA2), normally stable and nontoxic, can be activated specifically ...
Jianyu Wang, Zhongxing Xu, Lin Wang, Xin Sui, Yuan Luo, Xiuli Zhao, Jun Yang, Yongan Wang   +7 more
wiley   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Pain Modulation and Central Sensitization in Painful Diabetic Peripheral Neuropathy: Updated Narrative Review and Future Directions. [PDF]

J Diabetes
Ye D, Fairchild TJ, Vo L, Drummond PD.
europepmc   +1 more source

Editorial: Balancing Tumor Necrosis Factor Receptor I and Tumor Necrosis Factor Receptor II Jointly for Joint Inflammation [PDF]

Arthritis & Rheumatology, 2014
openaire   +2 more sources

Time‐Controlled Refrigerated Stem Cell Therapy Mitigates Scleroderma Fibrosis via Modulation of Mitochondrial Autophagy and Gut Metabolism

Advanced Science, EarlyView.
This study established an RT‐MSCs‐based therapeutic approach for scleroderma in mice. RT‐MSCs attenuated fibrosis by regulating mitochondrial autophagy and restored gut microbiota homeostasis. Metabolomic analyses confirmed recovery of key metabolites, and RT‐MSCs demonstrated favorable lesion targeting and safety profiles.
Xue Xia, Chenfei Kong, Xiaoming Zhao, Naixu Shi, Jinlan Jiang, Ping Li   +5 more
wiley   +1 more source

The dual roles of natural killer cells in liver immunity and tolerance: Implications for health and disease. [PDF]

Hepatol Commun
Li Z, Gong Y, Ye L, Liu W.
europepmc   +1 more source

Halofuginone is a Molecular Glue Degrader of Integrin β4

Advanced Science, EarlyView.
Integrin β4 overexpression is linked to aggressive tumors and poor prognosis, but targeted therapies are lacking. We identified halofuginone (HF) as a molecular glue degrader that promotes integrin β4 degradation via the CRL4BWDR18 E3 ligase. HF suppresses tumor progression in vitro and in vivo, offering a new strategy for targeting oncogenic ...
Wei Gong, Di Yang, Junrui Tian, Yufei Chai, Tiantian Yu, Qingnan Wu, Yan Wang, Weimin Zhang, Qimin Zhan   +8 more
wiley   +1 more source